Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2

Open access
Pineda‐Roman, Mauricio, Zangari, Maurizio, Haessler, Jeff, Anaissie, Elias, Tricot, Guido, Van Rhee, Frits, Crowley, John, Shaughnessy, John D., Barlogie, Bart · 2008 · British Journal of Haematology

Abstract

Summary: Total therapy 3 (TT3), incorporating bortezomib up‐front into a tandem transplant regimen for newly diagnosed multiple myeloma (MM), effected 2‐year complete response (CR) estimates >90%, which appeared superior to results reported for total therapy 2 (TT2). With median follow‐up times of 2 years with TT3 and 5 years with TT2, the clinical outcomes of 303 patients in the former and 668 in the latter trial were compared, including the subset of 607 patients with gene expression profiling (GEP) data. With similar baseline prognostic factors, event‐free survival (EFS) (P = 0·0002) and CR duration (P = 0·003) were superior with TT3 vs. TT2 with a strong trend noted also for improved overall survival (OS) (P = 0·16). In the GEP‐defined FGFR3 subgroup, TT3 imparted significantly superior OS, EFS and CR duration vis‐à‐vis TT2. Matching 300 patients each by standard prognostic factors, TT3 yielded superior EFS and CR duration and borderline superior OS. The advantage of TT3 still pertained when the comparison was limited to patients who completed TT2 consolidation rapidly within 24 months. Our data strongly suggest that the addition of bortezomib in TT3 was accountable for its superior performance rather than greater compliance with protocol completion as a result of greater dose‐density in TT3 vs. TT2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2007.06921.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 166

Metadata

Authors
Pineda‐Roman, M., Zangari, M., Haessler, J., Anaissie, E., Tricot, G., Van Rhee, F., Crowley, J., Shaughnessy, J. D., & Barlogie, B.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2008-02-21
Volume
140
Issue
6
Pages
625-634
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2072077329
Cited by
166
References
2
FWCI
13.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. https://app.cochat.ai/papers/10.1111/j.1365-2141.2007.06921.x
The paper
Pineda‐Roman, M., Zangari, M., Haessler, J., Anaissie, E., Tricot, G., Van Rhee, F., Crowley, J., Shaughnessy, J. D., & Barlogie, B. (2008). Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2007.06921.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.